Figure 1.

Effect of sodium glucose co-transporter-2 inhibition on kidney disease outcomes by diabetes status

Kidney disease progression was defined as a sustained decrease in eGFR (≥50%) from randomisation, a sustained low eGFR, end-stage kidney disease, or death from kidney failure in all presented trials. Outcome definition details for each trial are provided in the appendix (pp 9–11). Rate values are not presented for the combined subtotal and total populations due to the heterogeneity in rates across the individual trials. eGFR=estimated glomerular filtration rate. RR=relative risk. SGLT2i=sodium glucose co-transporter-2 inhibitor. NA=not available. *One participant without diabetes in DELIVER was missing a baseline creatinine measurement and was excluded.